NCT05625022

Lianhua Qingke for the Rehabilitation of Patient With Omicron Infection

Efficacy and Safety of Lianhua Qingke in the Long-term Rehabilitation of Patients With Omicron Infection: a 6-month Follow-up Study

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 2,000 (estimated)
• Sponsor: Qilu Hospital of Shandong University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The patients with Omicron infection usually have fever, respiratory symptoms, tachycardia, headache, toothache, muscle soreness, physical decline, and so on, while others are asymptomatic patients. It is urgent to find drugs to improve the long-term rehabilitation of symptomatic patients with Omicron infection and decrease the duration of viral shedding in both symptomatic and asymptomatic patients. This study aims to investigate the efficacy and safety of Lianhua Qingke tablets in patients with Omicron infection. The duration of viral shedding and symptoms will be evaluated. 6-month follow-up will be performed to evaluate the effect of Lianhua Qingke on long-term rehabilitation of all symptoms induced by Omicron infection, as well as infection events.

Conditions

• Coronavirus
• Traditional Chinese Medicine

Interventions

Type	Name	Description
DRUG	Lianhua Qingke tablets	Lianhua Qingke tablets: 4 tablets once, three times daily

Timeline

• Start date: 2022-11-01
• Primary completion: 2023-06-30
• Completion: 2023-12-31
• First posted: 2022-11-22
• Last updated: 2022-11-22

Locations

1 site across 1 country: China